Filing Flows

Filing Flows › IGC Pharma (IGC) › Next earnings date

IGC Pharma (IGC) earnings: matched the estimate

IGC Pharma (IGC) reported on Nov 6, 2026 and matched the EPS estimate: −$0.02 against −$0.02 (+0.0%). Revenue was $328K for Q3 2026, +72% year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result+0.0% vs estimate
Beat rate40%

The last report

IGC Pharma reported revenue of $328K for the third quarter 2026 (+72% Y/Y), net loss $2.0M: White Labeling Services $321K, Wellness and Lifestyle $7K. How it makes money → · Every quarter →

IGC Pharma: EPS against the estimate, last 5 reportsIGC Pharma: EPS against the estimate, last 5 reportsEstimateReported−$0.03−$0.02Feb 25−$0.02−$0.01Jun 25−$0.02−$0.02May 26−$0.02−$0.03Aug 26−$0.02−$0.02Nov 26
Latest (Nov 26): Estimate −$0.02, Reported −$0.02.

IGC Pharma's latest quarter

IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%, net loss $2.0M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did IGC Pharma beat earnings?

IGC Pharma (IGC) reported on Nov 6, 2026 and matched the EPS estimate: −$0.02 against −$0.02 (+0.0%).

When does IGC report earnings?

The next date is not set yet.

Does IGC Pharma usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.